Literature DB >> 18950300

Insulin-treated type 2 diabetes is associated with a decreased survival in heart failure patients after cardiac resynchronization therapy.

Maurizio Mangiavacchi1, Maurizio Gasparini, Stefano Genovese, Daniela Pini, Catherine Klersy, Renato Bragato, Bruno Andreuzzi, Annamaria Municinò, François Regoli, Paola Galimberti, Carlo Ceriotti, Edoardo Gronda.   

Abstract

BACKGROUND: Cardiac resynchronization therapy (CRT) improves cardiac performance and survival in patients with congestive heart failure. Recent observations suggest that diabetes is associated with a worse outcome in these patients. The aim of the study was to investigate the effect of diabetes and insulin treatment on outcome after CRT.
METHODS: Diabetic status and insulin treatment were assessed in 447 patients who underwent CRT (males 80.8%, mean age 65.7 +/- 9.7 years, ejection fraction 29.9 +/- 6.11%). Patients were stratified in three groups according to the presence or absence of diabetes and insulin treatment.
RESULTS: Nondiabetic patients were 366 (79.6%), noninsulin-treated diabetic patients 62 (13.9%), insulin-treated diabetic patients 29 (6.5%). The estimated death rate was 5.15 per 100 patients-year in the nondiabetic group, 8.63 in noninsulin-treated diabetics (HR 1.59, P = 0.240), and 15.84 in insulin-treated diabetics (HR 3.05, P = 0.004). Cardiac mortality accounted for 81% of deaths in nondiabetic patients and for 56% of deaths in diabetic patients. Diabetic patients tended to have a worse recovery of left ventricular ejection fraction over time (P = 0.057) and of the distance at 6-minute walking test (6MWT) (P = 0.018).
CONCLUSIONS: Insulin-treated diabetes is associated with a worse functional recovery and a higher mortality in patients with advanced heart failure after CRT. While cardiac death accounts for the majority of deaths in nondiabetic patients, a relevant proportion of the mortality in diabetic patients seem to result from noncardiac causes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18950300     DOI: 10.1111/j.1540-8159.2008.01206.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  14 in total

Review 1.  Clinical, laboratory, and pacing predictors of CRT response.

Authors:  Jagdesh Kandala; Robert K Altman; Mi Young Park; Jagmeet P Singh
Journal:  J Cardiovasc Transl Res       Date:  2012-02-24       Impact factor: 4.132

2.  Impact of diabetes mellitus on the clinical response to cardiac resynchronization therapy in elderly people.

Authors:  Celestino Sardu; Raffaele Marfella; Gaetano Santulli
Journal:  J Cardiovasc Transl Res       Date:  2014-02-06       Impact factor: 4.132

Review 3.  Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions.

Authors:  Shilpa Vijayakumar; Muthiah Vaduganathan; Javed Butler
Journal:  Circulation       Date:  2018-03-06       Impact factor: 29.690

4.  Usefulness of hemoglobin A(1c) to predict outcome after cardiac resynchronization therapy in patients with diabetes mellitus and heart failure.

Authors:  Ravi V Shah; Robert K Altman; Mi Young Park; Jodi Zilinski; Jordan Leyton-Mange; Mary Orencole; Michael H Picard; Conor D Barrett; E Kevin Heist; Gaurav Upadhyay; Ranendra Das; Jagmeet P Singh; Saumya Das
Journal:  Am J Cardiol       Date:  2012-05-25       Impact factor: 2.778

Review 5.  Implantable cardioverter defibrillators in diabetics: efficacy and safety in patients at risk of sudden cardiac death.

Authors:  Muhammad Shahreyar; Vijayadershan Mupiddi; Indrajit Choudhuri; Jasbir Sra; Abdul Jamil Tajik; Arshad Jahangir
Journal:  Expert Rev Cardiovasc Ther       Date:  2015-06-22

Review 6.  Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence.

Authors:  Yi Tan; Zhiguo Zhang; Chao Zheng; Kupper A Wintergerst; Bradley B Keller; Lu Cai
Journal:  Nat Rev Cardiol       Date:  2020-02-20       Impact factor: 32.419

Review 7.  Influence of diabetes on cardiac resynchronization therapy in heart failure patients: a meta-analysis.

Authors:  Hui Sun; Yuqing Guan; Lei Wang; Yong Zhao; Hong Lv; Xiuping Bi; Huating Wang; Xuejing Zhang; Li Liu; Min Wei; Hui Song; Guohai Su
Journal:  BMC Cardiovasc Disord       Date:  2015-03-21       Impact factor: 2.298

8.  Multipolar pacing by cardiac resynchronization therapy with a defibrillators treatment in type 2 diabetes mellitus failing heart patients: impact on responders rate, and clinical outcomes.

Authors:  Celestino Sardu; Michelangela Barbieri; Matteo Santamaria; Valerio Giordano; Cosimo Sacra; Pasquale Paolisso; Alessandro Spirito; Raffaele Marfella; Giuseppe Paolisso; Maria Rosaria Rizzo
Journal:  Cardiovasc Diabetol       Date:  2017-06-09       Impact factor: 9.951

9.  Influence of diabetes on left ventricular systolic and diastolic function and on long-term outcome after cardiac resynchronization therapy.

Authors:  Ulas Höke; Joep Thijssen; Rutger J van Bommel; Lieselot van Erven; Enno T van der Velde; Eduard R Holman; Martin J Schalij; Jeroen J Bax; Victoria Delgado; Nina Ajmone Marsan
Journal:  Diabetes Care       Date:  2012-12-05       Impact factor: 19.112

Review 10.  Cardiac Resynchronization Therapy Outcomes in Type 2 Diabetic Patients: Role of MicroRNA Changes.

Authors:  Celestino Sardu; Michelangela Barbieri; Maria Rosaria Rizzo; Pasquale Paolisso; Giuseppe Paolisso; Raffaele Marfella
Journal:  J Diabetes Res       Date:  2015-11-09       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.